City State Bank’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$69K Hold
1,440
0.02% 321
2026
Q1
$52.9K Buy
1,440
+400
+38% +$19K 0.01% 348
2025
Q4
$52.9K Hold
1,040
0.01% 342
2025
Q3
$57.7K Sell
1,040
-25
-2% -$1.46K 0.02% 326
2025
Q2
$73.5K Hold
1,065
0.02% 297
2025
Q1
$74K Hold
1,065
0.02% 295
2024
Q4
$91.6K Sell
1,065
-105
-9% -$11.4K 0.03% 263
2024
Q3
$139K Hold
1,170
0.05% 225
2024
Q2
$167K Buy
1,170
+40
+4% +$5.3K 0.07% 199
2024
Q1
$145K Buy
1,130
+1,000
+769% +$119K 0.06% 210
2023
Q4
$13K Buy
130
+50
+63% +$4.95K 0.01% 438
2023
Q3
$7K Hold
80
﹤0.01% 516
2023
Q2
$6K Hold
80
﹤0.01% 548
2023
Q1
$6K Buy
80
+10
+14% +$709 ﹤0.01% 542
2022
Q4
$5K Buy
+70
New +$4.1K ﹤0.01% 531

Other funds holding NVO

City State Bank's NVO Position: Q2 2026 in Review

City State Bank held its Novo Nordisk (NVO) position steady in Q2 2026 at 1,440 shares worth $69K. The position accounts for 0.02% of the portfolio, ranked #321.

City State Bank first reported a position in NVO in Q4 2022 and has held it in 15 quarters since. The position peaked at $167K in Q2 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • City State Bank held 1,440 shares of Novo Nordisk worth $69K as of Q2 2026.
  • City State Bank left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.02% of City State Bank's portfolio in Q2 2026, its #321 holding.
  • City State Bank first reported a position in Novo Nordisk in Q4 2022 and has held it in 15 quarters since.
  • City State Bank's Novo Nordisk position peaked at $167K in Q2 2024.
  • 580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on City State Bank's 13F filing for Q2 2026, filed 14 Jul 2026.